Table 2.
Cox proportional hazards model for 10‐year recurrence‐free survival in breast cancer patients (n = 39)
| Clinicopathological markers | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | CI 95% | P‐value | Hazard ratio | CI 95% | P‐value | |
|
Estrogen receptor Positive (vs negative) |
0.948 | 0.34–2.62 | 0.917 | – | ||
|
Progesterone receptor Positive (vs negative) |
1.34 | 0.49–3.71 | 0.570 | 7.79 | 1.65–39.78 | 0.009 |
|
HER2 Negative (vs positive) |
1.57 | 0.56–4.42 | 0.392 | – | ||
|
Ta 3 + 4 (vs + 1 + 2) |
2.60 | 0.92–7.37 | 0.072 | 0.15 | 0.03–0.73 | 0.019 |
|
Na 1–3 (vs 0) |
6.06 | 1.70–21.67 | 0.006 | 26.42 | 4.53–154.12 | <0.001 |
|
Histological grade 3 (vs 1 + 2) |
7.36 | 0.97–56.08 | 0.054 | – | ||
|
Age High (vs low) |
0.68 | 0.25–1.88 | 0.459 | – | ||
|
Type of surgery Mastectomy (vs lumpectomy) |
3.32 | 1.05–10.47 | 0.040 | 7.95 | 1.77–35.77 | 0.007 |
|
Ki67b High (vs low) |
1.63 | 0.58–4.57 | 0.358 | 15.67 | 2.61–94.24 | 0.003 |
a
Clinical tumor size and nodal status according to TNM staging system.
b
Median value for Ki67 = 38.6%. Bold values indicate significance level.
CI, confidence interval; HER2, human epidermal growth factor receptor 2.